Author's response to reviews

Title: Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOMETM10, a new liposomal amphotericin B

Authors:

Md Asad (asadseraphic.nii@gmail.com)
Pradyot Bhattacharya (p_pradyot@yahoo.com)
Nahid Ali (nali@iicb.res.in)

Version: 2 Date: 14 January 2015

Author's response to reviews: see over
To,
The Editor
BMC Infectious Diseases

15.01.2015

Dear Sir,

Please find attached our revised manuscript entitled “Therapeutic and immunomodulatory activities of a short-course treatment of murine visceral leishmaniasis with KALSOME™ 10, a new liposomal amphotericin B” by Md Asad, Pradyot Bhattacharya and Nahid Ali for consideration of publication in your esteemed journal.

Here, we have evaluated the efficacy, toxicity and immunomodulatory activity of a new liposomal formulation of amphotericin B, KALSOME™ 10 for the treatment of VL at single (3.5 mg/kg and 7.5 mg/kg) and double doses (7.5mg/kg). We found that treatment with 7.5 mg/kg double dose brought almost complete parasite clearance from both liver and spleen of infected BALB/c mice. Toxicity of the administered doses was studied for liver and kidney functions in normal mice and found that KALSOME™ 10 is not only effective against VL but also safe, having no hepatic and renal functioning impairments. Besides, treatment with KALSOME™ 10 causes an increased IL-12 and IFNγ and decreased IL-10 and TGFβ levels in infected mice splenocytes. Hence KALSOME™ 10 promotes protective response by suppressing disease promoting cytokines. Since, it maintains the inherent immunomodulatory property of amphotericin B, therapy with KALSOME™ 10 may also lead to life-long protection.

I hope this paper will generate interest in the area of drug delivery and its further evaluation will lead to development of a safe, low dose and cheap therapy for visceral leishmaniasis.

Thanking you,

Yours sincerely,

Nahid Ali